Baseline characteristics of patients by age group
| Characteristic . | ≥70 y . | <70 y . | P value . |
|---|---|---|---|
| No. of patients, N | 251 | 570 | |
| Age at infusion, y | <.01∗ | ||
| Median (min-max) | 74.3 (70.1-90.3) | 61.6 (29.3-69.9) | |
| ≥80, n (%) | 14 (5.6) | 0 (0.0) | |
| Sex, n (%) | .96∗ | ||
| Female | 103 (41.0) | 231 (40.5) | |
| Male | 148 (59.0) | 338 (59.3) | |
| Not reported | 0 (0.0) | 1 (0.2) | |
| Recipient race, n (%) | .13∗ | ||
| White | 212 (84.5) | 440 (77.2) | |
| Black or African American | 28 (11.2) | 92 (16.1) | |
| Asian | 8 (3.2) | 14 (2.5) | |
| Native Hawaiian or other Pacific Islander | 1 (0.4) | 1 (0.2) | |
| American Indian or Alaska Native | 0 (0.0) | 2 (0.4) | |
| >1 race | 0 (0.0) | 5 (0.9) | |
| Not reported | 2 (0.8) | 16 (2.8) | |
| Recipient ethnicity, n (%) | .08∗ | ||
| Hispanic or Latino | 10 (4.0) | 45 (7.9) | |
| Not Hispanic or Latino | 235 (93.6) | 516 (90.5) | |
| Not reported | 6 (2.4) | 9 (1.6) | |
| ECOG performance status category before infusion, n (%) | .18∗ | ||
| ECOG 0-1 | 215 (85.7) | 513 (90.0) | |
| ECOG ≥2 | 16 (6.4) | 26 (4.6) | |
| Not reported | 20 (8.0) | 31 (5.4) | |
| Clinically significant comorbidity, n (%) | .12∗ | ||
| No | 47 (18.7) | 142 (24.9) | |
| Yes | 204 (81.3) | 427 (74.9) | |
| Cytogenetic risk any time before infusion, n (%) | .57∗ | ||
| Standard risk | 167 (66.5) | 364 (63.9) | |
| High risk | 54 (21.5) | 142 (24.9) | |
| Not reported | 30 (12.0) | 64 (11.2) | |
| ISS stage before infusion, n (%) | .04∗ | ||
| I | 52 (20.7) | 158 (27.7) | |
| II | 54 (21.5) | 88 (15.4) | |
| III | 25 (10.0) | 43 (7.5) | |
| Not reported | 120 (47.8) | 281 (49.3) | |
| Extramedullary plasmacytomas, n (%) | .06∗ | ||
| No | 123 (49.0) | 280 (49.1) | |
| Yes | 17 (6.8) | 68 (11.9) | |
| Not reported | 111 (44.2) | 222 (38.9) | |
| Plasma cells in bone marrow >50% before infusion, n (%) | .11‡ | ||
| No | 140 (55.8) | 297 (52.1) | |
| Yes | 27 (10.8) | 44 (7.7) | |
| Not reported | 84 (33.5) | 229 (40.2) | |
| Penta-exposed before infusion, n (%) | .28∗ | ||
| No | 97 (38.6) | 233 (40.9) | |
| Yes | 153 (61.0) | 337 (59.1) | |
| Not reported | 1 (0.4) | 0 (0.0) | |
| Triple-class exposed before infusion, n (%) | .38∗ | ||
| No | 14 (5.6) | 30 (5.3) | |
| Yes | 236 (94.0) | 540 (94.7) | |
| Not reported | 1 (0.4) | 0 (0.0) | |
| Prior BCMA therapy, n (%) | .56‡ | ||
| No | 213 (84.9%) | 494 (86.6%) | |
| Yes | 39 (15.5%) | 80 (14.1%) | |
| Lymphodepleting chemotherapy regimen, n (%) | .04‡ | ||
| Cyclophosphamide + fludarabine | 217 (86.5) | 524 (91.9) | |
| Bendamustine | 22 (8.8) | 29 (5.1) | |
| Other | 11 (4.4) | 17 (3.0) | |
| Not reported | 1 (0.4) | 0 (0.0) | |
| Disease status before infusion, n (%) | .79‡ | ||
| CR/stringent CR | 4 (1.6) | 13 (2.3) | |
| VGPR | 17 (6.8) | 42 (7.4) | |
| PR | 28 (11.2) | 68 (11.9) | |
| NR/SD, PD, and relapse from CR | 200 (79.7) | 445 (78.1) | |
| Not reported | 2 (0.8) | 2 (0.4) | |
| Hemoglobin <8 g/dL before infusion, n (%) | .24∗ | ||
| No | 217 (86.5) | 471 (82.6) | |
| Yes | 30 (12.0) | 79 (13.9) | |
| Not reported | 4 (1.6) | 20 (3.5) | |
| Platelets <50 × 109/L before infusion, n (%) | .33∗ | ||
| No | 219 (87.3) | 479 (84.0) | |
| Yes | 27 (10.8) | 69 (12.1) | |
| Not reported | 5 (2.0) | 22 (3.9) | |
| ANC <1000 × 106/L before infusion, n (%) | .66§ | ||
| No | 222 (88.4) | 502 (88.1) | |
| Yes | 17 (6.8) | 33 (5.8) | |
| Not reported | 12 (4.8) | 35 (6.1) | |
| Total no. of cells administered, median (range), ×106 | 410 (312-460) | 409 (307-460) | .79∗ |
| Total no. of administered cells ≥400 × 106, n (%) | .97§ | ||
| No | 145 (57.8) | 330 (57.9) | |
| Yes | 101 (40.2) | 230 (40.4) | |
| Not reported | 5 (2.0) | 10 (1.8) |
| Characteristic . | ≥70 y . | <70 y . | P value . |
|---|---|---|---|
| No. of patients, N | 251 | 570 | |
| Age at infusion, y | <.01∗ | ||
| Median (min-max) | 74.3 (70.1-90.3) | 61.6 (29.3-69.9) | |
| ≥80, n (%) | 14 (5.6) | 0 (0.0) | |
| Sex, n (%) | .96∗ | ||
| Female | 103 (41.0) | 231 (40.5) | |
| Male | 148 (59.0) | 338 (59.3) | |
| Not reported | 0 (0.0) | 1 (0.2) | |
| Recipient race, n (%) | .13∗ | ||
| White | 212 (84.5) | 440 (77.2) | |
| Black or African American | 28 (11.2) | 92 (16.1) | |
| Asian | 8 (3.2) | 14 (2.5) | |
| Native Hawaiian or other Pacific Islander | 1 (0.4) | 1 (0.2) | |
| American Indian or Alaska Native | 0 (0.0) | 2 (0.4) | |
| >1 race | 0 (0.0) | 5 (0.9) | |
| Not reported | 2 (0.8) | 16 (2.8) | |
| Recipient ethnicity, n (%) | .08∗ | ||
| Hispanic or Latino | 10 (4.0) | 45 (7.9) | |
| Not Hispanic or Latino | 235 (93.6) | 516 (90.5) | |
| Not reported | 6 (2.4) | 9 (1.6) | |
| ECOG performance status category before infusion, n (%) | .18∗ | ||
| ECOG 0-1 | 215 (85.7) | 513 (90.0) | |
| ECOG ≥2 | 16 (6.4) | 26 (4.6) | |
| Not reported | 20 (8.0) | 31 (5.4) | |
| Clinically significant comorbidity, n (%) | .12∗ | ||
| No | 47 (18.7) | 142 (24.9) | |
| Yes | 204 (81.3) | 427 (74.9) | |
| Cytogenetic risk any time before infusion, n (%) | .57∗ | ||
| Standard risk | 167 (66.5) | 364 (63.9) | |
| High risk | 54 (21.5) | 142 (24.9) | |
| Not reported | 30 (12.0) | 64 (11.2) | |
| ISS stage before infusion, n (%) | .04∗ | ||
| I | 52 (20.7) | 158 (27.7) | |
| II | 54 (21.5) | 88 (15.4) | |
| III | 25 (10.0) | 43 (7.5) | |
| Not reported | 120 (47.8) | 281 (49.3) | |
| Extramedullary plasmacytomas, n (%) | .06∗ | ||
| No | 123 (49.0) | 280 (49.1) | |
| Yes | 17 (6.8) | 68 (11.9) | |
| Not reported | 111 (44.2) | 222 (38.9) | |
| Plasma cells in bone marrow >50% before infusion, n (%) | .11‡ | ||
| No | 140 (55.8) | 297 (52.1) | |
| Yes | 27 (10.8) | 44 (7.7) | |
| Not reported | 84 (33.5) | 229 (40.2) | |
| Penta-exposed before infusion, n (%) | .28∗ | ||
| No | 97 (38.6) | 233 (40.9) | |
| Yes | 153 (61.0) | 337 (59.1) | |
| Not reported | 1 (0.4) | 0 (0.0) | |
| Triple-class exposed before infusion, n (%) | .38∗ | ||
| No | 14 (5.6) | 30 (5.3) | |
| Yes | 236 (94.0) | 540 (94.7) | |
| Not reported | 1 (0.4) | 0 (0.0) | |
| Prior BCMA therapy, n (%) | .56‡ | ||
| No | 213 (84.9%) | 494 (86.6%) | |
| Yes | 39 (15.5%) | 80 (14.1%) | |
| Lymphodepleting chemotherapy regimen, n (%) | .04‡ | ||
| Cyclophosphamide + fludarabine | 217 (86.5) | 524 (91.9) | |
| Bendamustine | 22 (8.8) | 29 (5.1) | |
| Other | 11 (4.4) | 17 (3.0) | |
| Not reported | 1 (0.4) | 0 (0.0) | |
| Disease status before infusion, n (%) | .79‡ | ||
| CR/stringent CR | 4 (1.6) | 13 (2.3) | |
| VGPR | 17 (6.8) | 42 (7.4) | |
| PR | 28 (11.2) | 68 (11.9) | |
| NR/SD, PD, and relapse from CR | 200 (79.7) | 445 (78.1) | |
| Not reported | 2 (0.8) | 2 (0.4) | |
| Hemoglobin <8 g/dL before infusion, n (%) | .24∗ | ||
| No | 217 (86.5) | 471 (82.6) | |
| Yes | 30 (12.0) | 79 (13.9) | |
| Not reported | 4 (1.6) | 20 (3.5) | |
| Platelets <50 × 109/L before infusion, n (%) | .33∗ | ||
| No | 219 (87.3) | 479 (84.0) | |
| Yes | 27 (10.8) | 69 (12.1) | |
| Not reported | 5 (2.0) | 22 (3.9) | |
| ANC <1000 × 106/L before infusion, n (%) | .66§ | ||
| No | 222 (88.4) | 502 (88.1) | |
| Yes | 17 (6.8) | 33 (5.8) | |
| Not reported | 12 (4.8) | 35 (6.1) | |
| Total no. of cells administered, median (range), ×106 | 410 (312-460) | 409 (307-460) | .79∗ |
| Total no. of administered cells ≥400 × 106, n (%) | .97§ | ||
| No | 145 (57.8) | 330 (57.9) | |
| Yes | 101 (40.2) | 230 (40.4) | |
| Not reported | 5 (2.0) | 10 (1.8) |
ANC, absolute neutrophil count; CR, complete response; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; max, maximum; min, minimum; NR, no response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial remission.
Fisher exact test.
Pearson χ2 test.
Kruskal-Wallis test.